BioMérieux filed with the FDA seeking clearance and CLIA waiver for a rapid multiplex PCR vaginitis panel designed to return results in about 20 minutes at the point of care. The submission covers the BioFire SpotFire Vaginitis Panel (VG), intended to detect multiple common causes of vaginitis from a single vaginal swab. The test reports eight results covering bacterial vaginosis-associated bacterium markers, key Lactobacillus species, yeast species, and Trichomonas vaginalis, using an algorithm approach for relative abundance assessments and nucleic-acid detection for infectious targets. Clinically, the company is positioning the panel to speed treatment decisions within a single visit—an angle tied to reducing downstream risks associated with untreated infections and improving diagnostic workflow efficiency.